Effects of Irisin Hormone on Health and Energy Homeostasis

Year 2024, Volume: 8 Issue: 3, 294 - 303, 30.12.2024

Muhammed Enes Kartal , Özlem Baran

Abstract

Obesity is a significant public health issue with a growing prevalence linked to cardiovascular disease, type 2 diabetes mellitus, an
increased incidence of certain types of cancer, and respiratory complications. Adipose tissue and muscle tissue play important roles in
the management of obesity. Irisin, a myokine released from muscles, adipose tissue, and various tissues and organs, is a hormone that is
stimulated by exercise. In the literature search, PubMed, Science Direct and Google Scholar databases were searched and the structure,
release, role in energy metabolism and effects on obesity of irisin hormone were analysed comprehensively. Irisin is incorporated into
the circulatory system following the proteolysis of the C-terminal part of FNDC5, a cell membrane protein, by a protease that is yet to
be discovered. Released by myocytes, irisin is 12 kDa in size and consists of 112 amino acids. Irisin has a significant effect on energy
metabolism by increasing mitochondrial biogenesis and uncoupling protein-1 expression, thereby enhancing the conversion of white
adipose tissue to brown adipose tissue and promoting thermogenesis. As a result, energy expenditure increases significantly. Due to this
effect, it is thought that irisin may be beneficial for the treatment of obesity. However, the functions of the irisin hormone in various
tissues and organs, the receptors involved in these functions, and its effects on diseases have not yet been fully elucidated. Therefore,
further research on irisin, a promising hormone for regulating energy metabolism and preventing obesity, is warranted.

Keywords

Energy homeostasis, Irisin, Obesity

İrisin Hormonunun Sağlık ve Enerji Homeostazı Üzerine Etkileri

Abstract

Obezite; kardiyovasküler hastalık, tip-2 diyabetes mellitus, belirli kanser türlerinin görülme sıklığında artış ve solunum komplikasyonlarıyla
ilişkili, prevelansı günden güne artan önemli bir halk sağlığı sorunudur. Obezitenin yönetiminde adipoz doku ve kas dokusu
önemli bir rol oynamaktadır. Kaslardan, adipoz dokudan ve çeşitli doku ve organlardan salınan bir miyokin olan irisin, egzersizle
stimüle edilen bir hormondur. Literatür incelemesinde, PubMed, Science Direct ve Google Akademik veri tabanları taranarak, irisin
hormonunun yapısı, salınımı, enerji metabolizmasındaki rolü ve obezite üzerindeki etkileri kapsamlı bir şekilde analiz edilmiştir. İrisin,
henüz tam olarak keşfedilmeyen bir proteaz tarafından, bir hücre zarı proteini olan FNDC5’in C-terminal kısmının proteolizinin ardından
meydana gelerek sirkülatuar sisteme dahil olur. Miyositler tarafından salınan irisin, 12 kDa büyüklüğünde ve 112 aminoasitten
oluşmaktadır. İrisin, mitokondri biyogenezini ve uncoupling protein-1 ekspresyonunu artırarak enerji metabolizması üzerinde önemli
bir etkiye sahiptir, böylece beyaz adipoz dokunun kahverengi adipoz dokuya dönüşümünü ve termojenezi artırmaktadır. Bunun sonucu
olarak da enerji harcaması önemli ölçüde artar. Bu etkisiyle irisinin, obezitenin tedavisi açısından faydalı olabileceği düşünülmektedir.
Ancak irisin hormonunun çeşitli doku ve organlardaki işlevleri, bu işlevlerdeki görevli reseptörler ve hastalıklar üzerindeki etkileri
henüz bulunamamıştır. Bu sebeple enerji metabolizmasının regülasyonu ve obezitenin önlenmesi için umut vaat eden bir hormon olan
irisin hakkında daha fazla araştırmanın yapılması gerekmektedir.

Keywords

Enerji homeostazı, İrisin, Obezite

Ethical Statement

Derleme türünde bir çalışma olduğu için etik kurul oluru gerekmemiştir.

Supporting Institution

Bulunmamaktadır.

Thanks

Bulunmamaktadır.

References

• 1. Novelle MG, Contreras C, Romero-Picó A, López M, Diéguez C. Irisin, two years later. Int J Endocrinol. 2013;2013:746281.
• 2. Alemán JO, Almandoz JP, Frias JP, Galindo RJ. Obesity among Latinx people in the United States: A review. Obesity (Silver Spring). 2023;31(2):329-337.
• 3. Colaianni G, Cinti S, Colucci S, Grano M. Irisin and musculoskeletal health. Ann N Y Acad Sci. 2017;1402(1):5-9.
• 4. Lee JH, Jun HS. Role of Myokines in Regulating Skeletal Muscle Mass and Function. Front Physiol. 2019;30;10:42.
• 5. Polyzos SA, Kountouras J, Shields K, Mantzoros CS. Irisin: a renaissance in metabolism? Metabolism. 2013;62(8):1037-44.
• 6. Ferrer-Martínez A, Ruiz-Lozano P, Chien KR. Mouse PeP: a novel peroxisomal protein linked to myoblast differentiation and development. Dev Dyn. 2002;224(2):154-67.
• 7. Teufel A, Malik N, Mukhopadhyay M, Westphal H. Frcp1 and Frcp2, two novel fibronectin type III repeat containing genes. Gene. 2002;297(1-2):79-83.
• 8. Zhu B, Wang B, Zhao C, Wang Y, Zhou Y, Lin J, Zhao R. Irisin Regulates Cardiac Responses to Exercise in Health and Diseases: a Narrative Review. J Cardiovasc Transl Res. 2023;16(2):430-442.
• 9. Atherton PJ, Phillips BE. Greek goddess or Greek myth: the effects of exercise on irisin/FNDC5 in humans. J Physiol. 2013;591(21):5267-8.
• 10. Liu S, Cui F, Ning K, Wang Z, Fu P, Wang D, Xu H. Role of irisin in physiology and pathology. Front Endocrinol (Lausanne). 2022;13:962968.
• 11. Leung PS. The potential of irisin as a therapeutic for diabetes. Future Med Chem. 2017;9(6):529-532.
• 12. Huerta-Delgado AS, Roffe-Vazquez DN, Gonzalez-Gil AM, Villarreal-Calderón JR, Tamez-Rivera O, Rodriguez-Gutierrez NA, Castillo EC, Silva-Platas C, Garcia-Rivas G, Elizondo- Montemayor L. Serum Irisin Levels, Endothelial Dysfunction, and Inflammation in Pediatric Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome. J Diabetes Res. 2020;2020:1949415.
• 13. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Højlund K, Gygi SP, Spiegelman BM. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463-8.
• 14. Fu J, Han Y, Wang J, Liu Y, Zheng S, Zhou L, Jose PA, Zeng C. Irisin Lowers Blood Pressure by Improvement of Endothelial Dysfunction via AMPK-Akt-eNOS-NO Pathway in the Spontaneously Hypertensive Rat. J Am Heart Assoc. 2016;5(11):e003433.
• 15. Schumacher MA, Chinnam N, Ohashi T, Shah RS, Erickson HP. The structure of irisin reveals a novel intersubunit β-sheet fibronectin type III (FNIII) dimer: implications for receptor activation. J Biol Chem. 2013;288(47):33738-33744.
• 16. Waseem R, Shamsi A, Mohammad T, Hassan MI, Kazim SN, Chaudhary AA, Rudayni HA, Al-Zharani M, Ahmad F, Islam A. FNDC5/Irisin: Physiology and Pathophysiology. Molecules. 2022;27(3):1118.
• 17. Rabiee F, Lachinani L, Ghaedi S, Nasr-Esfahani MH, Megraw TL, Ghaedi K. New insights into the cellular activities of Fndc5/ Irisin and its signaling pathways. Cell Biosci. 2020;10:51.
• 18. Flori L, Testai L, Calderone V. The “irisin system”: From biological roles to pharmacological and nutraceutical perspectives. Life Sci. 2021;267:118954.
• 19. Mehrabian S, Taheri E, Karkhaneh M, Qorbani M, Hosseini S. Association of circulating irisin levels with normal weight obesity, glycemic and lipid profile. J Diabetes Metab Disord. 2016;15:17.
• 20. Akram S, Qureshi HJ. Irisin: A newly discovered novel myokine. JAMDC. 2022; 4(1): 31-37.
• 21. Fukushima Y, Kurose S, Shinno H, Thi Thu HC, Takao N, Tsutsumi H, Hasegawa T, Nakajima T, Kimura Y. Effects of Body Weight Reduction on Serum Irisin and Metabolic Parameters in Obese Subjects. Diabetes Metab J. 2016;40(5):386- 395.
• 22. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, Mantzoros CS. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012;61(12):1725-38.
• 23. Aslan, N. N., & Yardımcı, H. (2017). Obezite Üzerine Etkili Yeni Bir Hormon: İrisin. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi. 2017;6(3):176-183.
• 24. Luo Y, Qiao X, Xu L, Huang G. Irisin: circulating levels in serum and its relation to gonadal axis. Endocrine. 2022;75(3):663- 671.
• 25. Al-Daghri NM, Alkharfy KM, Rahman S, Amer OE, Vinodson B, Sabico S, Piya MK, Harte AL, McTernan PG, Alokail MS, Chrousos GP. Irisin as a predictor of glucose metabolism in children: sexually dimorphic effects. Eur J Clin Invest. 2014 ;44(2):119-24.
• 26. Anastasilakis AD, Polyzos SA, Saridakis ZG, Kynigopoulos G, Skouvaklidou EC, Molyvas D, Vasiloglou MF, Apostolou A, Karagiozoglou-Lampoudi T, Siopi A, Mougios V, Chatzistavridis P, Panagiotou G, Filippaios A, Delaroudis S, Mantzoros CS. Circulating irisin in healthy, young individuals: day-night rhythm, effects of food intake and exercise, and associations with gender, physical activity, diet, and body composition. J Clin Endocrinol Metab. 2014;99(9):3247-55.
• 27. Zügel M, Qiu S, Laszlo R, Bosnyák E, Weigt C, Müller D, Diel P, Steinacker JM, Schumann U. The role of sex, adiposity, and gonadectomy in the regulation of irisin secretion. Endocrine. 2016;54(1):101-110.
• 28. Scalzo RL, Peltonen GL, Giordano GR, Binns SE, Klochak AL, Paris HL, Schweder MM, Szallar SE, Wood LM, Larson DG, Luckasen GJ, Hickey MS, Bell C. Regulators of human white adipose browning: evidence for sympathetic control and sexual dimorphic responses to sprint interval training. PLoS One. 2014;9(6):e90696.
• 29. Baig, M. F., Khan, M. K. A., Perveen, M., Atif, M., Younas, U., & Sharif, S. Irisin and its Effects on the Metabolic Diseases: Irisin and its Effects on the Metabolic Diseases. Pakistan Bio- Medical Journal, 2023; 02-09.
• 30. Özge E, Arslan K, Özge HN, Altunoğlu EG. The Relationship Between Thyroid Diseases And Irisin Hormone. Mrr. 2022;5(1):1-9.
• 31. Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008;134(3):405-15.
• 32. Guardiola-Diaz HM, Rehnmark S, Usuda N, Albrektsen T, Feltkamp D, Gustafsson JA, Alexson SE. Rat peroxisome proliferator- activated receptors and brown adipose tissue function during cold acclimatization. J Biol Chem. 1999;274(33):23368- 77.
• 33. Löffler D, Müller U, Scheuermann K, Friebe D, Gesing J, Bielitz J, Erbs S, Landgraf K, Wagner IV, Kiess W, Körner A. Serum irisin levels are regulated by acute strenuous exercise. J Clin Endocrinol Metab. 2015;100(4):1289-99.
• 34. Hecksteden A, Wegmann M, Steffen A, Kraushaar J, Morsch A, Ruppenthal S, Kaestner L, Meyer T. Irisin and exercise training in humans - results from a randomized controlled training trial. BMC Med. 2013;11:235.
• 35. Fernandez-del-Valle M, Short M J, Chung E, McComb J, Kloiber S, et al. Effects of High-Intensity Resistance Training on Circulating Levels of Irisin in Healthy Adults: A Randomized Controlled Trial. Asian J Sports Med. 2018;9(2):e13025.
• 36. Mahgoub MO, D’Souza C, Al Darmaki RSMH, Baniyas MMYH, Adeghate E. An update on the role of irisin in the regulation of endocrine and metabolic functions. Peptides. 2018;104:15-23.
• 37. Qi JY, Yang LK, Wang XS, Wang M, Li XB, Feng B, Wu YM, Liu SB, Zhang K. Mechanism of CNS regulation by irisin, a multifunctional protein. Brain Res Bull. 2022;188:11-20.
• 38. Aydin, S., Kuloglu, T., Aydin, S., Kalayci, M., Yilmaz, M., Cakmak, T., Albayrak, S., Gungor, S., Colakoglu, N., & Ozercan, I. H. A comprehensive immunohistochemical examination of the distribution of the fat-burning protein irisin in biological tissues. Peptides. 2014:61;130–136.
• 39. Buscemi S, Corleo D, Buscemi C, Giordano C. Does iris(in) bring bad news or good news? Eat Weight Disord. 2018;23(4):431-442.
• 40. Hofmann T, Elbelt U, Stengel A. Irisin as a muscle-derived hormone stimulating thermogenesis--a critical update. Peptides. 2014;54:89-100.
• 41. Li H, Qin S, Liang Q, Xi Y, Bo W, Cai M, Tian Z. Exercise Training Enhances Myocardial Mitophagy and Improves Cardiac Function via Irisin/FNDC5-PINK1/Parkin Pathway in MI Mice. Biomedicines. 2021;9(6):701.
• 42. Lee P, Linderman JD, Smith S, Brychta RJ, Wang J, Idelson C, Perron RM, Werner CD, Phan GQ, Kammula US, Kebebew E, Pacak K, Chen KY, Celi FS. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab. 2014;19(2):302-9.
• 43. Chen N, Li Q, Liu J, Jia S. Irisin, an exercise-induced myokine as a metabolic regulator: an updated narrative review. Diabetes Metab Res Rev. 2016;32(1):51-9.
• 44. Cherkas LF, Hunkin JL, Kato BS, Richards JB, Gardner JP, Surdulescu GL, Kimura M, Lu X, Spector TD, Aviv A. The association between physical activity in leisure time and leukocyte telomere length. Arch Intern Med. 2008;168(2):154-8.
• 45. Kábrt J. Životní styl a riziko civilizačních nemocí [Live style and risk of lifestyle diseases]. Vnitr Lek. 2014;60(5-6):458-61.
• 46. Lackland DT, Voeks JH. Metabolic syndrome and hypertension: regular exercise as part of lifestyle management. Curr Hypertens Rep. 2014;16(11):492.
• 47. Blizzard LeBlanc DR, Rioux BV, Pelech C, Moffatt TL, Kimber DE, Duhamel TA, Dolinsky VW, McGavock JM, Sénéchal M. Exercise-induced irisin release as a determinant of the metabolic response to exercise training in obese youth: the EXIT trial. Physiol Rep. 2017;5(23):e13539.
• 48. Rashid FA, Abbas HJ, Naser NA, Addai Ali H. Effect of Long-Term Moderate Physical Exercise on Irisin between Normal Weight and Obese Men. Scientific World Journal. 2020;1897027.
• 49. Lu Y, Li H, Shen SW, Shen ZH, Xu M, Yang CJ, Li F, Feng YB, Yun JT, Wang L, Qi HJ. Swimming exercise increases serum irisin level and reduces body fat mass in high-fat-diet fed Wistar rats. Lipids Health Dis. 2016;15:93.
• 50. Yang XQ, Yuan H, Li J, Fan JJ, Jia SH, Kou XJ, Chen N. Swimming intervention mitigates HFD-induced obesity of rats through PGC-1α-irisin pathway. Eur Rev Med Pharmacol Sci. 2016;20(10):2123-30.
• 51. Yang Z, Chen X, Chen Y, Zhao Q. Decreased irisin secretion contributes to muscle insulin resistance in high-fat diet mice. Int J Clin Exp Pathol. 2015;8(6):6490-7.
• 52. Peterson JM, Mart R, Bond CE. Effect of obesity and exercise on the expression of the novel myokines, Myonectin and Fibronectin type III domain containing 5. PeerJ. 2014;2:e605.
• 53. Pekkala S, Wiklund PK, Hulmi JJ, Ahtiainen JP, Horttanainen M, Pöllänen E, Mäkelä KA, Kainulainen H, Häkkinen K, Nyman K, Alén M, Herzig KH, Cheng S. Are skeletal muscle FNDC5 gene expression and irisin release regulated by exercise and related to health? J Physiol. 2013;591(21):5393-400.
• 54. Pardo M, Crujeiras AB, Amil M, Aguera Z, Jiménez-Murcia S, Baños R, Botella C, de la Torre R, Estivill X, Fagundo AB, Fernández-Real JM, Fernández-García JC, Fruhbeck G, Gómez- Ambrosi J, Rodríguez R, Tinahones FJ, Fernández-Aranda F, Casanueva FF. Association of irisin with fat mass, resting energy expenditure, and daily activity in conditions of extreme body mass index. Int J Endocrinol. 2014;2014:857270.
• 55. Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity--correlation with body mass index. Peptides. 2013;39:125-30.
• 56. Crujeiras AB, Pardo M, Arturo RR, Navas-Carretero S, Zulet MA, Martínez JA, Casanueva FF. Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and following weight regain in obese men and women. Am J Hum Biol. 2014;26(2):198-207.
• 57. Vaughan RA, Gannon NP, Mermier CM, Conn CA. Irisin, a unique non-inflammatory myokine in stimulating skeletal muscle metabolism. J Physiol Biochem. 2015;71(4):679-89.
• 58. Korta P, Pocheć E, Mazur-Biały A. Irisin as a Multifunctional Protein: Implications for Health and Certain Diseases. Medicina (Kaunas). 2019;55(8):485.
• 59. Bidares M, Safari-Kish B, Abedi M, Malekzadeh-Shoushtari H, Jasemnezhad M, Azarbayejani N, Aziz M, Jahromi SP, Fouladi S, Azizi-Soleiman F. The Effect of Bariatric Surgery on Irisin Level: a Systematic Review and Meta-analysis. Obes Surg. 2023;33(10):3256-3265.
• 60. Ma Y, Du Y, Yang J, He Q, Wang H, Lin X. Anti-inflammatory effect of Irisin on LPS-stimulated macrophages through inhibition of MAPK pathway. Physiol Res. 2023;72(2):235-249.
• 61. Ren Y, Zhang J, Wang M, Bi J, Wang T, Qiu M, Lv Y, Wu Z, Wu R. Identification of irisin as a therapeutic agent that inhibits oxidative stress and fibrosis in a murine model of chronic pancreatitis. Biomed Pharmacother. 2020;126:110101.
• 62. Zhang Y, Zhao L, Gao H, Zhai J, Song Y. Potential role of irisin in digestive system diseases. Biomed Pharmacother. 2023;166:115347.
• 63. Zhu W, Sahar NE, Javaid HMA, Pak ES, Liang G, Wang Y, Ha H, Huh JY. Exercise-Induced Irisin Decreases Inflammation and Improves NAFLD by Competitive Binding with MD2. Cells. 2021;10(12):3306.
• 64. Huang L, Yan S, Luo L, Yang L. Irisin regulates the expression of BDNF and glycometabolism in diabetic rats. Mol Med Rep. 2019;19(2):1074-1082.
• 65. Ahmed TM, Nassar M, Mohamed HAA, Elhadidy KE, Farhan HM, El Basset ASA, Elmessiery RM, Kamel MF. Evaluation of serum levels of Irisin as a marker of endothelial dysfunction in patients with type 2 diabetes mellitus. Endocrinol Diabetes Metab. 2023;6(3):e403.
• 66. Celik Z, Baygutalp NK, Kilic AF, Tekin SB, Bakan E, Gul MA, Yuce N. Serum irisin levels in colorectal cancer patients. Eur Rev Med Pharmacol Sci. 2023;27(4):1474-1479.
• 67. Ercan Z, Dogru MS, Ertugrul NU, Yardimci A, Canpolat S. The Effect of Irisin on Thyroid Hormone Levels in Chronic Paroxetine- Treated Rats. Biol Trace Elem Res. 2023;201(2):810- 815.
• 68. Park KH, Zaichenko L, Peter P, Davis CR, Crowell JA, Mantzoros CS. Diet quality is associated with circulating C-reactive protein but not irisin levels in humans. Metabolism. 2014;63(2):233-41.